U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082803) titled 'A Study of TLN-121 in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas' on June 26.
Brief Summary: The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Study Start Date: June 23
Study Type: INTERVENTIONAL
Condition:
Lymphoma
Lymphoma, Non Hodgkin
Intervention:
DRUG: TLN-121
Specified dose on specified days.
DRUG: TLN-254
Specified dose on specified days.
DRUG: TLN-121
Specified dose on specified days.
R...